March 04, 2015 10:18 AM ET

Healthcare Equipment and Supplies

Company Overview of Sequent Medical, Inc.

Company Overview

Sequent Medical, Inc., a medical device company, develops catheter-based devices for neurovascular specialists and their patients. The company develops WEB Aneurysm Embolization System, a platform that advances therapeutic options for ruptured and un-ruptured cerebral aneurysms. It serves customers in Europe and other countries. Sequent Medical, Inc. was incorporated in 2006 and is based in Aliso Viejo, California with operations in Bonn, Germany.

11A Columbia

Aliso Viejo, CA 92656

United States

Founded in 2006





Key Executives for Sequent Medical, Inc.

Chief Executive Officer, President and Director
Age: 50
Founder and Chairman
Founder, Chief Technology Officer, Vice President and Director
Chief Financial Officer and Vice President
Age: 59
Vice President of Quality Assurance & Regulatory Compliance
Compensation as of Fiscal Year 2014.

Sequent Medical, Inc. Key Developments

Sequent Medical Announces Approval to Utilize Latest Generation WEB Devices in U.S. IDE Study

Sequent Medical announced that the U.S. Food and Drug Administration has approved the inclusion of the SL ("Single Layer") family of WEBTM Aneurysm Embolization Device devices for use in its U.S. Investigational Device Exemption ("IDE") clinical study called WEB-IT. Patient enrollments in WEB-IT have already been completed utilizing the SL family. Compared to previous versions of the WEB device family, the SL family offers a lower delivery profile, improved navigability, and enhanced visualization. The SL configurations are made possible by further advancement of Sequent Medical's proprietary MicroBraid TM technology. The SL family consists of two separate product configurations, the WEB SL and WEB SLS, each with a distinct shape designed to accommodate varying aneurysm morphologies.

Sequent Medical, Inc. Announces Prospective Clinical Data on Web Aneurysm Embolization System

Sequent Medical, Inc. announced the presentation of results from WEBCAST, a prospective study of the WEB Aneurysm Embolization System at the European Society of Minimally Invasive Neurological Therapy (ESMINT) Congress. The study examined safety and aneurysm occlusion rates in 51 patients with complex wide neck bifurcation aneurysms treated with the WEB across ten European centers. The study met the primary efficacy endpoint demonstrating 85.4% adequate and stable occlusion without retreatment at six months follow-up. The study also demonstrated good safety at thirty days and six months, with 0% procedure-related morbidity and mortality. These encouraging results add to a growing body of clinical evidence for the WEB including the recently initiated WEB-IT Investigational Device Exemption study in the United States, two ongoing European prospective, multicenter studies fifteen peer-reviewed clinical publications, and nearly 1,000 patients treated with the WEB.

Sequent Medical, Inc. Launches New SL Family of Web Aneurysm Embolization Devices

Sequent Medical, Inc. announced that it has received CE mark for the SL family of WEB(R) Aneurysm Embolization Devices, and has commenced a controlled release of these new models in select neurovascular centers in Europe. The SL family offers a lower profile and superior navigability that will enable physicians to treat a broader range of aneurysms with the WEB platform. The SL configurations are made possible by further advancement of company's proprietary MicroBraid(TM) technology, a dense mesh constructed from a large number of extremely fine Nitinol wires. Unlike conventional medical braids, MicroBraid features a mix of wire diameters and high wire counts to achieve a tailored balance of compliance, porosity and profile across device sizes. The SL family consists of two separate product configurations, the WEB SL and WEB SLS, each with a distinct shape designed to accommodate varying aneurysm morphologies. Both configurations are available in multiple sizes ranging from 4-11 mm and are designed for delivery through Sequent Medical's VIA microcatheters. The WEB SL and WEB SLS will build upon the growing experience with the original dual layer WEB, now referred to as the WEB DL configuration, which has now been used to treat over 280 ruptured and unruptured aneurysms in Europe and Latin America.

Similar Private Companies By Industry

Company Name Region
Sanbor Medical Corporation United States
Estrogenics United States
NanoPharm LLC United States
Cantimer, Inc. United States
CryoXtract Instruments, LLC United States

Recent Private Companies Transactions

Private Placement
March 27, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sequent Medical, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at